372 related articles for article (PubMed ID: 28166468)
1. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
Chiuzan C; Shtaynberger J; Manji GA; Duong JK; Schwartz GK; Ivanova A; Lee SM
J Biopharm Stat; 2017; 27(3):477-494. PubMed ID: 28166468
[TBL] [Abstract][Full Text] [Related]
2. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
[TBL] [Abstract][Full Text] [Related]
3. Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.
Colin P; Micallef S; Delattre M; Mancini P; Parent E
Stat Med; 2015 Sep; 34(22):2999-3016. PubMed ID: 26059319
[TBL] [Abstract][Full Text] [Related]
4. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
Guo B; Li Y
Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
[TBL] [Abstract][Full Text] [Related]
5. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
[TBL] [Abstract][Full Text] [Related]
6. A novel framework of Bayesian optimal interval design for phase I trials with late-onset toxicities.
Zhou H; Chen C; Sun L; Zeng Z
Contemp Clin Trials; 2021 Jun; 105():106404. PubMed ID: 33862287
[TBL] [Abstract][Full Text] [Related]
7. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
Drilon A; Eaton AA; Schindler K; Gounder MM; Spriggs DR; Harris P; Ivy SP; Iasonos A; Lacouture ME; Hyman DM
Cancer; 2016 Apr; 122(8):1228-37. PubMed ID: 26916138
[TBL] [Abstract][Full Text] [Related]
8. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
Postel-Vinay S; Collette L; Paoletti X; Rizzo E; Massard C; Olmos D; Fowst C; Levy B; Mancini P; Lacombe D; Ivy P; Seymour L; Le Tourneau C; Siu LL; Kaye SB; Verweij J; Soria JC
Eur J Cancer; 2014 Aug; 50(12):2040-9. PubMed ID: 24880774
[TBL] [Abstract][Full Text] [Related]
9. Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.
Lee SM; Backenroth D; Cheung YK; Hershman DL; Vulih D; Anderson B; Ivy P; Minasian L
J Clin Oncol; 2016 Apr; 34(12):1395-401. PubMed ID: 26926682
[TBL] [Abstract][Full Text] [Related]
10. An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials.
Sato H; Hirakawa A; Hamada C
Stat Med; 2016 Oct; 35(23):4093-109. PubMed ID: 27221807
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials.
Gupta S; Hunsberger S; Boerner SA; Rubinstein L; Royds R; Ivy P; LoRusso P
J Natl Cancer Inst; 2012 Dec; 104(24):1860-6. PubMed ID: 23169991
[TBL] [Abstract][Full Text] [Related]
12. Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials.
Hazim A; Mills G; Prasad V; Haslam A; Chen EY
J Natl Compr Canc Netw; 2020 Apr; 18(4):428-433. PubMed ID: 32259790
[TBL] [Abstract][Full Text] [Related]
13. The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years.
van Brummelen EM; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):235-42. PubMed ID: 26960536
[TBL] [Abstract][Full Text] [Related]
14. Early phase trial designs and endpoints for targeted therapies in rare genotype subsets.
Mandrekar SJ
Am Soc Clin Oncol Educ Book; 2014; ():e107-10. PubMed ID: 24857087
[TBL] [Abstract][Full Text] [Related]
15. [Dose finding methods for targeted agents: new perspectives].
Paoletti X; Postel-Vinay S; Servois V; Doussau A; Ollivier L; Le Tourneau C
Bull Cancer; 2010 Dec; 97(12):1485-95. PubMed ID: 21220226
[TBL] [Abstract][Full Text] [Related]
16. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials.
Paoletti X; Geoerger B; Doz F; Baruchel A; Lokiec F; Le Tourneau C
Eur J Cancer; 2013 Jul; 49(10):2392-402. PubMed ID: 23540589
[TBL] [Abstract][Full Text] [Related]
17. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
Braun TM; Alonzo TA
Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization.
Riviere MK; Yuan Y; Jourdan JH; Dubois F; Zohar S
Stat Methods Med Res; 2018 Feb; 27(2):466-479. PubMed ID: 26988926
[TBL] [Abstract][Full Text] [Related]
19. The changing landscape of phase I trials in oncology.
Wong KM; Capasso A; Eckhardt SG
Nat Rev Clin Oncol; 2016 Feb; 13(2):106-17. PubMed ID: 26552953
[TBL] [Abstract][Full Text] [Related]
20. Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan.
Shimomura A; Kondo S; Kobayashi N; Iwasa S; Kitano S; Tamura K; Fujiwara Y; Yamamoto N
Int J Clin Oncol; 2017 Aug; 22(4):780-785. PubMed ID: 28293794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
